Subscriber Content Preview | Request a free trialSearch  
  Go

Healthcare

Don't swallow that poison pill! Use a buyout shop instead

Companies under siege from activists may turn to private equity firms as 'white squires.' Playing such a role represents a potentially profitable new business opportunity, but it also cuts against the buyout industry's traditionally collaborative approach. Continue reading

Treasury takes small steps to rein in inversions

The measure does little to change tax rules as the Obama administration disavows desire to bar the move outright. Continue reading

Belize brokers arrested after 2-year FBI stock manipulation probe

The brokers have been tied to numerous suspected pump and dumps of U.S. stocks. Continue reading

Siga seeks bankruptcy shelter

The biological warfare defense company files for Chapter 11 because of a pending judgment that could total $232 million. Continue reading

Twinlab goes public again via reverse merger

The transaction follows a management buyout that implied a $150 million valuation to the vitamin maker. Continue reading

Voce loses ConMed proxy fight after executive changes

Activist investor had called the medical device maker's strategic review process "brief and controversial." Continue reading

Lew's upcoming inversion talk to widen spreads

Mergers driven by tax avoidance are becoming a hot topic in Washington. Continue reading

Roche and InterMune, a strategic play in the midst of inversions

The $8.3 billion transaction could signal M&A for the sake of strategy, rather than tax inversion. Continue reading

ConMed proxy contest e-mails reveal bitter fight

An unusual release of feints between company and activist show positioning before board vote. Continue reading

Broken levy: How U.S. tax law encourages inversions

As companies seek better treatment by relocating overseas, pressure builds to reform a system rooted in the imperial era. As one critic points out, "doing nothing borders on the irresponsible." Continue reading

Roche acquires InterMune for $8.3B

Deal for California drug maker will bring a respiratory treatment drug under Roche's banner. Continue reading

Marijuana investor plans hedge fund to invest in reverse mergers

Leslie Bocskor is also forming a consulting firm to assist state governments in setting up regulatory guidelines for cannabis use. Continue reading

Meet the journalists

Pamela Taulbee

Senior Writer: Healthcare

Jim Cramer's 2013 M&A predictions

The Founder of TheStreet.com and host of Mad Money makes his predictio ... Video

More Healthcare video

The Deal's Webcast Series

If you have not had the chance to enjoy our Webcast Series, now is the time. Join these free 60-minute discussions and get a handle on the latest strategies and tactics in private equity, cross-border and middle market dealmaking and more.

Industry Events

View information on all upcoming industry events which The Deal representatives are participating in.

The Deal Economy Event

The Deal’s senior journalists host the industry's leading M&A forecasting event, an invitation-only gathering of influential members of the deal community discussing the outlook for dealmaking in the coming year.

The Deal on Twitter

Follow @TheDealNewsroom for the latest news across mergers and acquisitions, auctions, financings, restructurings and more!